Add to ORKGeffi cacy and patient safety related to the use of drotre-cogin alfa (DrotAA) is timely, principally due to the ne-gative results observed in clinical studies performed after the PROWESS study, and the economic cost-related impact of the drug on the healthcare system. The aim of this study was to review the main studies on the use of DrotAA in patients with severe sepsis
Introduction Several studies have indicated that early identification and treatment of patients with...
PURPOSE: This retrospective study was conducted to follow out acute intoxications with neuroleptics ...
Drotrecogin alfa (activated) is a new agent that may substantially affect the treatment of patients ...
OBJECTIVE: To demonstrate that drotrecogin alfa (activated) has an acceptable safety profile 1 yr fr...
INTRODUCTION: We performed a study to determine whether an enrollment sequence effect noted in the P...
Administration of drotrecogin alfa (activated) has been demonstrated to reduce mortality in patients...
Drotecogin alfa (activated; DrotAA) was approved in 2001 by the US Food and Drug Administration for ...
Purpose: To enhance the understanding of severe sepsis, a database of patients from multiple clinica...
PURPOSE: To enhance the understanding of severe sepsis, a database of patients from multiple clinica...
Severe sepsis and septic shock are common in the critically ill patient and account for considerable...
OBJECTIVE: INDEPTH is an integrated database of five trials enrolling patients with severe sepsis. I...
Background: Drotrecogin alfa (activated) 11 [DrotAA] is the only specific sepsis therapy that has be...
Sepsis remains a challenge for intensive care physicians, as it keeps up with high mortality rate in...
Objective: To assess the effects of drotrecogin alfa (activated) therapy, a recombinant human activa...
D ow nloaded from 2Warfarin has been in clinical use for nearly 60 years, and in 2010 there were ove...
Introduction Several studies have indicated that early identification and treatment of patients with...
PURPOSE: This retrospective study was conducted to follow out acute intoxications with neuroleptics ...
Drotrecogin alfa (activated) is a new agent that may substantially affect the treatment of patients ...
OBJECTIVE: To demonstrate that drotrecogin alfa (activated) has an acceptable safety profile 1 yr fr...
INTRODUCTION: We performed a study to determine whether an enrollment sequence effect noted in the P...
Administration of drotrecogin alfa (activated) has been demonstrated to reduce mortality in patients...
Drotecogin alfa (activated; DrotAA) was approved in 2001 by the US Food and Drug Administration for ...
Purpose: To enhance the understanding of severe sepsis, a database of patients from multiple clinica...
PURPOSE: To enhance the understanding of severe sepsis, a database of patients from multiple clinica...
Severe sepsis and septic shock are common in the critically ill patient and account for considerable...
OBJECTIVE: INDEPTH is an integrated database of five trials enrolling patients with severe sepsis. I...
Background: Drotrecogin alfa (activated) 11 [DrotAA] is the only specific sepsis therapy that has be...
Sepsis remains a challenge for intensive care physicians, as it keeps up with high mortality rate in...
Objective: To assess the effects of drotrecogin alfa (activated) therapy, a recombinant human activa...
D ow nloaded from 2Warfarin has been in clinical use for nearly 60 years, and in 2010 there were ove...
Introduction Several studies have indicated that early identification and treatment of patients with...
PURPOSE: This retrospective study was conducted to follow out acute intoxications with neuroleptics ...
Drotrecogin alfa (activated) is a new agent that may substantially affect the treatment of patients ...